REV1 and malignant mesothelioma: In a study of 139 malignant mesothelioma patients receiving cisplatin-based chemotherapy, carriers of the REV1 rs3087386 A allele were less prone to develop grade 2-4 neutropenia (OR = 0.38; 95% CI: 0.17–0.84; p = 0.017) (Goričar et al., 2014).